Inter Parfums (IPAR) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Achieved record third quarter net sales of $425M, up 15.4% year-over-year, and nine-month sales of $1.09B, up 10.3% year-over-year, driven by new brands Lacoste and Roberto Cavalli and robust global fragrance demand.
Net income attributable to Interparfums, Inc. was $62.3M for Q3 2024 (up 17% YoY) and $140.1M for the nine months (down 1.5% YoY); diluted EPS for Q3 was $1.93–$1.94.
Strongest sales growth in Western Europe (+25%), Asia-Pacific (+15%), North America (+12%), Central/South America (+20%), and Eastern Europe (+23%).
European operations contributed 67% of net sales; US operations 33%, with both segments benefiting from new brand launches.
Under-penetration in China noted; strategic entry planned for 2026.
Financial highlights
Gross margin for Q3 was 63.9%, unchanged year-over-year; nine-month gross margin at 63.6%, with full-year 2024 expected at ~64%.
Q3 operating margin was 25.0% (up 130 bps YoY); nine-month operating margin at 21.9% (down 160 bps YoY).
SG&A expenses rose 12% in Q3 and 16% year-to-date, representing 38.9% and 41.8% of net sales, respectively.
Advertising and promotion expenses increased 6% in Q3 to 15.7%–16% of net sales; year-to-date A&P at 16.6%.
Net cash from operating activities improved to $76M in Q3 from $18M prior year.
Outlook and guidance
2024 guidance reaffirmed: net sales of $1.45B, upper single-digit to double-digit Q4 growth, and record EPS of $5.15.
Initial 2025 guidance to be provided on November 12, 2024; management expects more moderate, sustainable growth.
Management anticipates continued growth, supported by a robust brand portfolio and upcoming product launches, including holiday programs and Roberto Cavalli Wild Heart duo.
Latest events from Inter Parfums
- Record sales and EPS in FY2025, with strong brand growth and steady 2026 outlook.IPAR
Q4 202525 Feb 2026 - Record Q2 sales and margin gains support strong outlook and new launches for 2025.IPAR
Q2 20242 Feb 2026 - Record sales, robust innovation, and 4% growth outlook with higher dividend for 2025.IPAR
Q4 20242 Feb 2026 - Q1 2025 net sales up 5%, net income $42.5M, margins and guidance strong, key licenses renewed.IPAR
Q1 20252 Feb 2026 - Q3 2025 sales up 1%, net income up 6%, FY2025 sales seen at $1.47B, EPS $5.12.IPAR
Q3 202520 Jan 2026 - Annual meeting to vote on directors, executive pay, and share cancellation, with board support.IPAR
Proxy Filing1 Dec 2025 - Key votes include director elections, executive pay approval, and cancellation of 'hook shares.'IPAR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, pay, name change, and auditor, all board-recommended.IPAR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, executive pay, name change, and auditor ratification.IPAR
Proxy Filing1 Dec 2025